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Abstract 
Cancer cachexia is a major cause of patient morbidity and mortality, with no efficacious 
treatment or management strategy. Despite sharing pathophysiological features with a 
number of neuromuscular wasting conditions, including age-related sarcopenia, the 
mechanisms underlying cachexia remain poorly understood. Studies of related conditions 
suggest that pathological targeting of the neuromuscular junction (NMJ) may play a key role 
in cachexia, but this has yet to be investigated in human patients. Here, high-resolution 
morphological analyses were undertaken on NMJs of rectus abdominis obtained from 
patients undergoing upper GI cancer surgery compared with controls (N=30; n=1,165 NMJs). 
Cancer patients included those with cachexia and weight-stable disease. Despite the low 
skeletal muscle index and significant muscle fibre atrophy in patients with cachexia, NMJ 
morphology was fully conserved. No significant differences were observed in any of the pre- 
and post-synaptic variables measured. We conclude that NMJs remain structurally intact in 
rectus abdominis in both cancer and cachexia, suggesting that denervation of skeletal muscle 
is not a major driver of pathogenesis. The absence of NMJ pathology is in stark contrast to 
related conditions, such as age-related sarcopenia, and supports the hypothesis that intrinsic 
changes within skeletal muscle, independent of any changes in motor neurons, represent the 
primary locus of neuromuscular pathology in cancer cachexia. 
 
 
Introduction 
 
Cachexia is a severe and debilitating syndrome, commonly associated with cancer and 
characterised by the loss of muscle, with or without corresponding loss of adipose tissue (1). 
Cancer cachexia is a major burden for both patients and health care systems globally, with 
profoundly negative impacts on the response to treatment, quality of life, and long-term 
survival of patients (2). At present, the consensus definition of cancer cachexia confirms loss 
of skeletal muscle as a key feature of the condition (3), largely mediated by pro-inflammatory 
cytokines and tumor-associated mediators, resulting in the activation of catabolic pathways 
in skeletal muscle (4). In this regard, cancer cachexia shares many of the muscle-specific and 
systemic inflammatory pathways common to the muscular dystrophies (5,6).  
 
Although the majority of research to date has focused on muscle abnormalities as the major 
locus of pathophysiology in cachexia, many lines of evidence have implicated the 
neuromuscular junction (NMJ) as a critical and early mediator of neuromuscular dysfunction 
and breakdown. Principally, NMJ dysfunction and denervation represent a shared hallmark of 
several related muscle wasting conditions and neuromuscular diseases (7-9). For example, 
NMJ pathology is considered to represent a key early driver of neuromuscular defects in age-
related sarcopenia (10-12), at least in part the result of an age-related loss of motor neurons 
(13). As cancer cachexia and sarcopenia share similar molecular mechanisms (14), and as 
cachexia is considered to be a multifactorial syndrome that includes components of both age-
related sarcopenia and bed rest/reduced physical activity (15), the NMJ has similarly been 
implicated in the pathogenesis of cachexia. The identification of displaced mononuclei in 
muscle of cachectic patients and C26 tumor-bearing mice has been used to suggest the 
presence of denervation (16). Furthermore, a member of the ubiquitin-proteasome pathway 
(MuRF1) pivotal to muscle wasting in tumor-bearing mice (and other murine models of 
muscle wasting) is critical for maintenance of the NMJ (17). Additionally, recent mouse 
studies of mTOR signalling, a key regulator of protein synthesis that is suppressed by 
inflammatory mediators in cancer cachexia (18), have shown that muscle specific-deletion of 
mTOR or Raptor results in muscle fibrillation and NMJ fragmentation (19). 
 
The role of the nerve-muscle interface in human cachexia is therefore of interest to both 
clinician and basic scientists, and relevant to our understanding of disease pathophysiology 
and the development of effective treatments. Thus, cancer cachexia has been the subject of 
co-culture/informatics projects (20) and ongoing patient studies. Experimental evidence 
supporting a direct role for NMJs in human cachexia is however highly reliant on studies of 
animal models of related conditions (21-23). Significantly, recent data have revealed striking 
and unexpected differences between the cellular and molecular anatomy of human NMJs 
compared to those of other model organisms (24), suggesting that findings from animal 
models may not be directly applicable to human patients.  
 
The present study builds upon our recent work establishing a robust protocol to facilitate the 
sampling and high-resolution, quantitative morphological analyses of human NMJs from 
patients undergoing surgery (24,25). We have adapted these protocols to facilitate a 
comprehensive analysis of the NMJ in patients with cancer cachexia.  
 
 
Results and Discussion 
 
To investigate the role of the NMJ in human cancer cachexia, we performed a comprehensive 
morphometric analysis of the NMJ in samples of rectus abdominis (RA) muscle obtained from 
patients undergoing surgery for upper GI cancer (Supplementary Table 1). RA was selected 
for two reasons: i) it is readily accessible in the majority of surgical approaches to the 
abdomen and therefore a well-utilized muscle for sampling and characterisation of human 
cancer cachexia (26); ii) nerve roots innervating RA are unlikely to be affected by 
radiculopathy or other common spinal pathology, rendering neurogenic remodelling an 
unlikely possibility.  
 
Cachectic patients demonstrated significantly lower skeletal muscle index (SMI) by CT criteria 
compared with weight stable patients (Supplementary Table 1) and also demonstrated a 
trend towards lower subcutaneous adiposity and higher visceral adiposity. These two body 
composition phenomena are associated with worsened outcomes in cancer patients (27-29) 
further confirming the cachectic patients as a high-risk group. Two patients in the weight 
stable cancer group exhibited a small degree of weight loss, but were not cachectic by the 
consensus definition (3,30). 
 
To confirm/validate the patient groupings based on the clinical and radiological guidelines (% 
weight loss and SMI, respectively) we assessed muscle fibre diameter on teased muscle fibre 
preparations from RA. Mean muscle fibre diameter was significantly reduced (by almost 15%) 
in the cachectic patients compared to both control and weight stable groups (p < 0.0001; 
Figure 1). However, there was no significant difference in mean muscle fibre diameter 
between control patients and those with weight stable disease (p > 0.05; Figure 1). These 
observations are in keeping with published data showing marked muscle fibre atrophy in 
cachexia (31,32) and support the patient group allocations based on consensus definition (3). 
 
Given that muscle fibre atrophy would be predicted to result from and/or lead to NMJ 
instability based on findings from animal studies (8,9) we next performed an initial qualitative 
assessment of NMJs. Despite the presence of muscle fibre atrophy in cachectic patients, NMJ 
morphology was indistinguishable from that observed in weight stable and control patients 
(Figure 2). NMJs of all three cohorts were noted to display the typical ‘nummular’ morphology 
characteristic of human NMJs (24) and despite the predicted heterogeneity in form across the 
complete pool of NMJs (Figure 3) we found no evidence of gross pathological changes or 
denervation of skeletal muscle fibres. 
 
Although initial qualitative observations suggested an absence of gross pathology at the NMJ, 
more subtle changes in NMJ morphology could still have been present in the cachectic 
patients. We therefore undertook a comprehensive NMJ-morph analysis of all patient NMJs 
(Figure 3; Supplementary Table 2). NMJs from RA were initially compared with our existing 
database of human NMJs from several lower limb muscles (24) to determine their likeness (or 
otherwise) to established human NMJ morphology in other muscle groups. NMJ-morph 
analysis revealed comparable NMJ morphology across RA and four lower limb muscles 
(Supplementary Figure 2). 
 
Quantitative NMJ-morph analyses confirmed that there were no significant differences in any 
aspect of NMJ morphology in RA across the three patient groups (Figure 3; Supplementary 
Table 2). Crucially, and in stark contrast to predictions based on mechanistic animal models, 
there was no evidence of denervation (defined by % overlap between nerve terminal and 
endplate), demonstrating that this is not a major feature of pathogenesis in cachectic 
patients. Similarly, there was no evidence for increased NMJ fragmentation, a classical feature 
of NMJ pathology found in animal models of neurodegeneration (7-9) and cardiac cachexia 
(33).  
 
Alongside analyses of denervation and NMJ fragmentation, our NMJ-morph analysis 
confirmed no statistically-significant changes in any of the other morphological variables 
investigated (Figure 3; Supplementary Table 2); similar axon diameters (~1µm) were observed 
across all 3 groups with no evidence of axonal swelling, neurofilament accumulation or 
polyneuronal innervation (indicative of denervation/reinnervation processes). Thus, neither 
gross nor subtle perturbations at the NMJ were observed in cachectic patients. However, the 
relative contribution of muscle regeneration and myopathic changes still requires definitive 
demonstration in human cachexia patients.  
 
It should be noted that cachectic patients in the current study represent the more extreme 
end of the clinical diagnostic definition criteria, having both weight loss and low CT 
muscularity. However, our study only enrolled patients who were eligible for surgery with 
potentially curative intent. It is not possible, therefore, to draw conclusions concerning a 
possible late disruption of the NMJ in palliative cancer patients with refractory cachexia and 
severe functional impairment.  
 
Whilst RA proved to be an excellent muscle for the current study, our findings differed from 
those observed in human age-related sarcopenia and in animal models of muscle wasting, 
both situations where weight-bearing muscles are usually assessed experimentally. It remains 
possible therefore that skeletal muscle with different functional and/or biochemical 
properties may respond differently in cachexia. Equally, the observed differences between 
human patients and animal models may reflect anticipated differences in cachexia 
pathophysiology between the two. Human cachexia is proposed to be a multifactorial 
condition in which diverse drivers of muscle wasting all contribute to varying degrees in 
individual patients and tumor types (15). In comparison, in vivo tumor-bearing models may 
demonstrate accelerated wasting, which lacks the complexity and heterogeneity of the 
human condition. This supposition is supported by previous studies that have demonstrated 
little overlap in gene expression profiles between muscle biopsies from human cancer 
patients and equivalent animal models (34).  
 
All patients received intravenous atracurium besilate during anesthesia, which competitively 
displaces acetylcholine from its receptors. Its half-life is 17-21 minutes, but whether it has 
longer-lasting effects on the form or function of the NMJ is not known (35). Importantly 
therefore, samples from the current study were compared with lower limb samples from 
patients who had received spinal anesthesia only. No differences were observed, suggesting 
that the choice of anesthetic was unlikely to have had any significant impact on the 
morphology of the NMJ.  
 
In summary, we report that the human NMJ retains full structural integrity in both cachexia 
and weight stable cancer. This suggests that denervation of skeletal muscle and/or NMJ 
disruption are not major drivers of disease pathogenesis in cancer cachexia and that cancer 
cachexia represents a unique neuromuscular condition that needs to be differentiated from 
related conditions, including age-related sarcopenia. This observation supports the 
hypothesis that intrinsic changes within skeletal muscle, independent of any changes in motor 
neurons, represent the primary locus of pathology in cachexia. Since the NMJ remains intact 
in patients with cancer cachexia, promotion of muscle hypertrophy using exercise and neural 
stimulation should remain a viable therapeutic intervention for future clinical trials. 
 
Methods 
Patient recruitment 
Patients with a confirmed diagnosis of gastrointestinal (GI) cancer suitable for surgical 
resection with curative intent were recruited from the regional multi-disciplinary team 
meeting (n = 20; Supplementary Table 1) and comprised patients with both cancer cachexia 
(n = 10) and weight stable disease (n = 10) based on consensus definition (Fearon et al. 2011). 
Suitable age-matched control patients undergoing a range of elective abdominal procedures 
(e.g. repair of aortic aneurysm or donor nephrectomy) were also recruited (n = 10; 
Supplementary Table 1). All patients were at least 18 years of age and provided written 
informed consent (inclusion criteria). Patients with a previous history of malignancy were not 
eligible for the control cohort (exclusion criteria).  
 Body composition analysis 
See supplement. 
  
Tissue sampling 
Tissue sampling was performed under general anesthesia at the start of the surgical 
procedure. If patients underwent neoadjuvant chemotherapy, surgery was performed 4 to 6 
weeks following cessation of treatment. Biopsies of rectus abdominis (RA) muscle were 
obtained following initial opening of the abdomen. RA is a well-characterised tissue for the 
study of human cancer cachexia, for which the results of previous studies have been reviewed 
recently (26). Evident changes of wasting, including fibre atrophy, have been robustly and 
repeatedly observed in several studies (32). RA has an ‘in-series’ architecture, with motor 
endplate bands located throughout its length (36). To ensure successful sampling, a 
longitudinal strip of muscle lying between two contiguous tendinous intersections was 
obtained using sharp dissection (approx. 0.5 x 0.5 x 2.0 cm). Samples were immediately fixed 
in 4% paraformaldehyde (PFA) for approximately 2 hours, followed by washing and storage 
in 1xPBS. 
  
Tissue processing and NMJ immunohistochemistry 
See supplement.  
 
Confocal imaging & NMJ-morph analysis 
See supplement.  
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 Software. Results are expressed 
as mean (± SEM). Group comparison of normally distributed data (based on D’Agostino-
Pearson test, P > 0.05) was performed by one-way ANOVA and Tukey’s post hoc test; non-
parametric data was analysed by Kruskal-Wallis test and Dunn’s post hoc test. P < 0.05 was 
considered to be significant. 
 
Study approval  
Ethics approval for tissue sampling was granted by the NHS Lothian Ethics Committee (IRAS 
190214) in accordance with the Helsinki Declaration. 
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Figures & Legends 
 
 
 
Figure 1.  Atrophy of skeletal muscle fibres in cancer cachexia. Upper panel shows a box and 
whisker plot of muscle fibre diameters (MFD) in control (n = 10 patients), weight stable (n = 
10) and cachectic (n = 10) patients. Bottom panels are representative micrographs of single, 
teased muscle fibres from control (left), weight stable (middle) and cachectic (right) patients. 
Scale bars = 50µm. Cachectic patients had significantly reduced muscle fibre diameters 
compared with weight stable and control cases (control n = 388, weight stable n = 362, 
cachexia n = 400 muscle fibres). The box contains the mean (+) and median (line) muscle fibre 
diameters for the group and encloses the central 90% of the data; the whiskers represent the 
SEM; outlying data points are shown beyond the whiskers. One-way ANOVA paired with a 
Tukey’s post-hoc test (****P < 0.0001). Individual p-values are in Supplementary Table 2. 
 
 
 
 
 
Figure 2.  Conservation of NMJ morphology in cancer cachexia. Confocal micrographs of 
representative small, medium and large-sized NMJs from RA in the three patient groups. 
Despite heterogeneity in size and shape of individual NMJs, overall morphology was 
conserved across all groups, with no evidence of NMJ pathology in either the cachexia or 
weight stable groups. Axon and nerve terminals in green (2H3/SV2) and AChRs of the motor 
endplate in red (α-BTX). Scale bars = 10 µm. 
 
 
 
 
 
 
 
 
 
Figure 3. Structural integrity of the NMJ in cancer cachexia. Morphometric analysis using 
NMJ-morph revealed that NMJ morphology is conserved in both cachexia and weight stable 
disease. Data presented as a pair of charts (scatterplot, above; box & whisker plot, below) for 
key NMJ variables, including measurements of pre- and post-synaptic architecture and axon 
diameter. Scatterplots depict the ~40 individual NMJs (data points) for the 10 patients (1 to 
10) in each group; the mean NMJ value is given by the red line; the observed heterogeneity 
is a normal feature of human NMJ morphology. Box and whisker plots constructed using the 
mean patient data in each group (10 patients; control NMJs n = 387, weight stable NMJs n = 
386, cachexia NMJs n = 392). The box contains the mean (+) and median (line) values for each 
NMJ variable and encloses the central 90% of the data; the whiskers represent the SEM. One-
way ANOVA paired with a Tukey’s post-hoc test. 
